Navigation Links
Decision Biomarkers Launches System for Faster, Easier Quantification of Protein Biomarkers
Date:1/18/2008

WALTHAM, Mass., Jan. 18 /PRNewswire/ -- Decision Biomarkers Inc., a leading developer of protein biomarker analysis systems for pharmaceutical research and development, announced the launch of the AVANTRA(TM) biomarker workstation along with its innovative MAX BIOCHIP(TM) 8-plex cytokine immunoassay. The system's ease-of-use enables users to generate data in real-time, accelerating decision making and improving project productivity.

The AVANTRA(TM) biomarker workstation is the first multiplexed immunoassay system that enables non-specialized technicians to perform complex protein biomarker analyses in both the lab and directly at clinical trial sites. Plasma and serum samples can be analyzed on site by virtually anyone in real time. The system eliminates the need to send samples out to a specialized lab.

One emerging application for DBI's technology is adaptive clinical trials where data is needed quickly for fast decision making. "Plasma and serum samples can now be analyzed on-site immediately after collection, lowering costs and streamlining the clinical-trials process" commented Roger Dowd, President and CEO of Decision Biomarkers. 'With the growing trend in adaptive clinical trials, rapidly acquiring data with the AVANTRA(TM) -- an hour after collection, versus several weeks or months from a core lab -- greatly accelerates decision making and the progress of clinical trials."

Researchers in biomarker validation, preclinical and translational medicine programs are interested as well. According to Peter Maimonis, VP Biological Research at Decision Biomarkers, "By fully automating the multiplexed protein assay, we specifically designed the AVANTRA(TM) system with individual investigators and researchers in mind. The scientists that we target want to spend their time on higher value activities rather than focusing on the minutia of running immunoassays."

The new MAX BIOCHIP(TM) immunoassay cartridges providing fully automated and multiplexed immunoassays complement the AVANTRA(TM) workstation. The 8-plex cytokine biochip introduced with the AVANTRA(TM) is positioned to support research in inflammation, autoimmune response, oncology, infectious disease and vaccines. Other immunoassay biochips are planned for introduction later this year including a 10-plex angiogenesis panel and multiplex cardiovascular panel. DBI is also developing biomarker panels with customized content defined by the Company's collaborators.

About Decision Biomarkers Inc.

Decision Biomarkers is a privately-held life science tools company that has developed the next-generation technology for protein biomarker analysis. DBI is driving the widespread adoption of protein biomarker analysis with the first automated, multiplex immunoassay system that can be used in real-time by virtually anyone, anywhere in drug development, clinical trials and diagnostics.

http://www.decisionbiomarkers.com

Copyright (C) 2008 Decision Biomarkers Inc. All rights reserved.


'/>"/>
SOURCE Decision Biomarkers Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
2. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
3. Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
4. Scientists Using Social Media to Inform Lab Purchasing Decisions
5. NPS Pharmaceuticals to Report Third Quarter 2007 Financial Results and Nycomed Decision on GATTEX(TM) Partnership on November 1, 2007
6. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
7. New Data Reveal Ethnicity May Play Role in Weight Loss Decisions
8. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
9. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
10. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
11. Consumer Advocates Praise Interstate Stem Cell Open Meeting Decision
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- Bioethics International, a not-for-profit organization focused on the ethics and ... accessible to patients around the world, today announced that the ... of the Good Pharma Scorecard an ,Editors, ... one of BMJ Open ,s ,Most Popular Articles, which ... frequently read. Ed Sucksmith , assistant editor of ...
(Date:2/11/2016)... , Feb. 11, 2016  Dovetail Genomics™ LLC today ... beta program for a planned metagenomic genome assembly service. ... company,s metagenomic genome assembly method in a talk on ... Biology & Technology conference in Orlando, Fla. ... highly complex datasets is difficult. Using its proprietary ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... announced a new agreement with Bankok,Thailand-based Global Stem Cells Network (GSCN) to distribute ... 15 Latin American countries, including Mexico, Costa Rica, Dominican Republic, Colombia, Argentina, Nicaragua, ...
(Date:2/10/2016)... ANNAPOLIS, Md. , Feb. 10, 2016  The ... E. Busch , has announced that University of Maryland ... MD, PhD, MBA and University of Maryland Medical System ... recipients of the "Speaker,s Medallion," the highest honor given ... House of Delegates. Dean Reece and ...
Breaking Biology Technology:
(Date:2/3/2016)... -- --> --> ... Identification System Market by Component (Hardware and Software), Search ... Government, Healthcare, and Transportation) and Geography - Global Forecast ... to be worth USD 8.49 Billion by 2020 at ... The transformation and technology evolution from the manual process ...
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint Inhibitors ... Rising Market Are you interested in the ... revenues for checkpoint inhibitors. Visiongain,s report gives those ... product and national level. Avoid falling behind ... progress, opportunities and revenues those emerging cancer therapies ...
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first day ... announced plans to develop a first of its kind ... of IBM Watson. In the first application of ... (NYSE: IBM ), and Welltok will create a ... assessments with cognitive analytics, delivered on Welltok,s health optimization ...
Breaking Biology News(10 mins):